What is Innate Pharma?
Founded in 1999, Innate Pharma S.A. operates at the intersection of immunology and oncology. The company is dedicated to the discovery and development of first-in-class therapeutic antibodies that modulate the immune system to fight cancer. By focusing on high-potential targets within the tumor microenvironment, Innate Pharma has established a robust portfolio of clinical-stage assets. Its market position is defined by a rigorous scientific approach and a commitment to addressing unmet medical needs through precision medicine and strategic partnerships with global pharmaceutical entities.
How much funding has Innate Pharma raised?
Innate Pharma has raised a total of $212M across 8 funding rounds:
Series A
$4.4M
Series B
$24.4M
Other Financing Round
$20M
Series C
$16.9M
Share Placement
$22.9M
Share Placement
$56.3M
Debt
$32.5M
Stock/Share Issuance
$34.7M
Series A (2000): $4.4M with participation from Sofinnova Partners, Auriga Partners, and Gimv
Series B (2002): $24.4M led by Gimv, Gilde Healthcare, Akka Venture, Sofinnova Partners, Auriga Partners, and Ardian
Other Financing Round (2002): $20M supported by Alta Partners, Auriga, Gilde Biotech & Nutrition, Pechel Industries, Sofinnova Partners, Innoveris, Axa Private Equity, and GIMV
Series C (2004): $16.9M, investors not publicly disclosed
Share Placement (2013): $22.9M backed by QVT Financial, OrbiMed, and Redmile Group
Share Placement (2014): $56.3M, investors not publicly disclosed
Debt (2022): $32.5M led by BNP Paribas and Societe Generale
Stock/Share Issuance (2026): $34.7M, investors not publicly disclosed
Key Investors in Innate Pharma
OrbiMed
OrbiMed Advisors LLC is a specialized investment firm focused on the healthcare sector, managing capital across biopharmaceuticals and medical devices with a deep understanding of innovation cycles.
Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, acting as a hands-on company builder across the entire value chain from seed to later-stage investments.
GIMV
Gimv is a European investment company specializing in partnering with mid-market businesses in the life sciences and healthcare sectors to foster sustainable, long-term growth.
What's next for Innate Pharma?
Looking ahead, the recent infusion of capital is expected to accelerate the progression of Innate Pharma's lead candidates through critical clinical trial phases. The strategic allocation of these funds will likely prioritize the expansion of ongoing research programs and the optimization of manufacturing processes for its antibody-based therapies. As the company navigates the complexities of the oncology market, it remains well-positioned to leverage its deep scientific expertise to achieve key regulatory milestones and enhance its competitive standing in the global biotech sector.
See full Innate Pharma company page
